About The Study: While cardioprotective glucose-lowering therapies were not associated with an overall reduction in all-cause dementia, this meta-analysis of randomized clinical trials found that glucose lowering with glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a statistically significant reduction in all-cause dementia.
Corresponding Author: To contact the corresponding author, Catriona Reddin, MD, email reddin.catriona@gmail.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2025.0360)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.0360?guestAccessKey=1c8d3837-4f9a-48df-8c7a-b37ca17d4b14&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040725
JAMA Neurology